Contrast media as carriers for local drug delivery -: Successful inhibition of neointimal proliferation in the porcine coronary stent model

被引:99
作者
Scheller, B
Speck, U
Romeike, B
Schmitt, A
Sovak, M
Böhm, M
Stoll, HP
机构
[1] Charite, Inst Radiol, Berlin, Germany
[2] Univ Saarlandes Kliniken, Inst Neuropathol, Holmbergh, Germany
[3] Univ Calif San Diego, Sch Med, Dept Radiol, San Diego, CA 92103 USA
[4] Univ Saarlandes Kliniken, Homburg, Germany
关键词
restenosis; stents; angioplasty; contrast media; taxanes; protaxel; lopromide;
D O I
10.1016/S0195-668X(03)00317-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Lipophilic taxanes can be dissolved in contrast media at significantly higher concentration than in saline. As contrast media have occasionally been observed to delineate the contour of coronary arteries for some seconds they may serve as a matrix for an anti proliferative drug aimed at preventing restenosis. The aim of this study was to test a novel taxane-contrast agent formulation for this new approach in the setting of coronary stenting. Methods and results In cell culture experiments (bovine vascular smooth muscle cells), 60-min incubation with contrast agent-taxane formulations (iopromide-paclitaxel, iopromide-protaxel) induced a significant, concentration-dependent inhibition of vascular smooth muscle cell (VSMC) proliferation over 12 days. Shorter incubation times of 10 and 3 min showed the same efficacy. For in vivo investigation, 16 stents were implanted into the coronary arteries of eight pigs using a 1.3 to 1 overstretch ratio. A control group received iopromide 370 alone while the treatment group was injected with a iopromide-protaxel formulation at a dose of 74 mumol/l, which is far below protaxel. levels inducing systemic toxicity. Quantitative angiography and histomorphometry of the stented arteries asserted statistic equality of the baseline parameters between the control and treatment groups. After 28 days, the treatment group showed a marked reduction of the parameters characterizing in-stent restenosis, especially a 34% reduction of the neointimal area. Conclusions First evidence is provided that using a contrast agent as solvent for a taxane constitutes a new drug delivery mechanism able to inhibit in-stent restenosis in the porcine restenosis model. (C) 2003 Published by Elsevier Ltd on behalf of The European Society of Cardiology.
引用
收藏
页码:1462 / 1467
页数:6
相关论文
共 19 条
[1]  
Axel DI, 1997, CIRCULATION, V96, P636
[2]   Arterial paclitaxel distribution and deposition [J].
Creel, CJ ;
Lovich, MA ;
Edelman, ER .
CIRCULATION RESEARCH, 2000, 86 (08) :879-884
[3]   Initial results of the quanam drug eluting stent (QuaDS-QP-2) registry (BARDDS) in human subjects [J].
de la Fuente, LM ;
Miano, J ;
Mrad, J ;
Penaloza, E ;
Yeung, AC ;
Eury, R ;
Froix, M ;
Fitzgerald, PJ ;
Stertzer, SH .
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2001, 53 (04) :480-488
[4]   Pathological analysis of local delivery of paclitaxel via a polymer-coated stent [J].
Farb, A ;
Heller, PF ;
Shroff, S ;
Cheng, L ;
Kolodgie, FD ;
Carter, AJ ;
Scott, DS ;
Froehlich, J ;
Virmani, R .
CIRCULATION, 2001, 104 (04) :473-479
[5]   Use of paclitaxel in patients with pre-existing cardiomyopathy: A review of our experience [J].
Gollerkeri, A ;
Harrold, L ;
Rose, M ;
Jain, D ;
Burtness, BA .
INTERNATIONAL JOURNAL OF CANCER, 2001, 93 (01) :139-141
[6]  
Heldman AW, 2001, CIRCULATION, V103, P2289
[7]   Local paclitaxel delivery for the prevention of restenosis:: Biological effects and efficacy in vivo [J].
Herdeg, C ;
Oberhoff, M ;
Baumbach, A ;
Blattner, A ;
Axel, DI ;
Schröder, S ;
Heinle, H ;
Karsch, KR .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (07) :1969-1976
[8]   Intrapericardial paclitaxel delivery inhibits neointimal proliferation and promotes arterial enlargement after porcine coronary overstretch [J].
Hou, DM ;
Rogers, PI ;
Toleikis, PM ;
Hunter, W ;
March, KL .
CIRCULATION, 2000, 102 (13) :1575-1581
[9]   PHARMACOKINETICS OF PACLITAXEL AND METABOLITES IN A RANDOMIZED COMPARATIVE-STUDY IN PLATINUM-PRETREATED OVARIAN-CANCER PATIENTS [J].
HUIZING, MT ;
KEUNG, ACF ;
ROSING, H ;
VANDERKUIJ, V ;
HUININK, WWT ;
MANDJES, IM ;
DUBBELMAN, AC ;
PINEDO, HM ;
BEIJNEN, JH .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (11) :2127-2135
[10]   Prevention of coronary restenosis - The evolving evidence base for radiation therapy [J].
Kuntz, RE ;
Baim, DS .
CIRCULATION, 2000, 101 (18) :2130-2133